Phase 1 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with recurrent and/or refractory solid tumors (ACTengine IMA201-101)
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / email@example.com
The goal of the study is to learn if it is safe to give genetically changed T cells (IMA201) in combination with standard of care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of IMA201 and if the study drug can help to control the disease. Cancers include: Breast cancer, esophageal cancer, gynecologic cancers, head and neck/oral cancers, liver cancer, lung cancer, skin cancer, and pancreatic cancer.
This study is closed
Ran Reshef, MD
|Are you at least 18 years of age?
|Do you have recurrent or refractory solid tumors, including non-small cell lung cancer or head and neck squamous cell carcinoma?
|Are you willing to undergo testing, such as biopsies and blood draws?